Church & Dwight Co
About: Church & Dwight is the leading global producer of baking soda. Beyond baking soda, the products in its portfolio have vast category reach, including laundry products, cat litter, oral care, deodorant, and nasal care, all sold under the Arm & Hammer brand. Its mix also includes Batiste, OxiClean, Vitafusion, WaterPik, Hero, and TheraBreath, which together with Arm & Hammer constitute around 70% of its annual sales and profits. Even as it works to extend the reach of its products, Church & Dwight still derives more than 80% of its sales from its home market in the US.
Employees: 5,550
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% less funds holding
Funds holding: 1,007 [Q2] → 1,005 (-2) [Q3]
1% less capital invested
Capital invested by funds: $22.4B [Q2] → $22B (-$334M) [Q3]
2% less first-time investments, than exits
New positions opened: 85 | Existing positions closed: 87
2.31% less ownership
Funds ownership: 88.31% [Q2] → 86.0% (-2.31%) [Q3]
19% less repeat investments, than reductions
Existing positions increased: 319 | Existing positions reduced: 394
29% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 10 (-4) [Q3]
56% less call options, than puts
Call options by funds: $33.8M | Put options by funds: $77.5M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
5 analyst ratings
Barclays Lauren Lieberman 43% 1-year accuracy 39 / 91 met price target | 20%downside $85 | Underweight Maintained | 5 Nov 2024 |
Deutsche Bank Steve Powers 58% 1-year accuracy 11 / 19 met price target | 8%upside $115 | Buy Maintained | 4 Nov 2024 |
TD Cowen Robert Moskow 46% 1-year accuracy 21 / 46 met price target | 10%upside $117 | Buy Maintained | 4 Nov 2024 |
JP Morgan Andrea Teixeira 40% 1-year accuracy 21 / 53 met price target | 7%downside $99 | Underweight Maintained | 4 Nov 2024 |
Wells Fargo Chris Carey 33% 1-year accuracy 11 / 33 met price target | 8%upside $115 | Overweight Maintained | 4 Nov 2024 |
Financial journalist opinion
Based on 3 articles about CHD published over the past 30 days